T. Rowe Price Associates, Inc.
Baltimore, Maryland, United StatesFounded 1937
T. Rowe Price Associates, Inc. focuses its venture capital efforts on identifying innovative private companies with the potential for durable long-term growth, often taking a long-term view and seeking higher expected returns due to the inherent risks. Their strategy involves rigorous fundamental research to uncover companies that can scale from early-stage to successful public entities, with some strategies also incorporating environmental, social, and governance (ESG) factors and alignment with UN Sustainable Development Goals.
Portfolio
6
Fund Size
—
Top Stage
Series F
Last 12 Mo
0
Team
GD
Greg Dunham
Vice President
Stage Distribution
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Rapport Therapeutics | Series B | $150M | Aug 2023 |
| Freenome | Series D | $300M | Dec 2021 |
| UiPath | Series F | $750M | Feb 2021 |
| DELFI Diagnostics, Inc. | Series A | $100M | Jan 2021 |
| UiPath | Series D | $568M | Apr 2019 |
| Lookout | Series F | $150M | Aug 2014 |
Top Co-Investors
Goldman Sachs2 shared
Accel2 shared
Cormorant Asset Management2 shared
Perceptive Advisors2 shared
Sands Capital2 shared
Coatue Management2 shared
Dragoneer Investment Group2 shared
Sequoia Capital2 shared
Khosla Ventures1 shared
Index Ventures1 shared
Andreessen Horowitz1 shared
Sofinnova Partners1 shared
ARCH Venture Partners1 shared
RA Capital Management1 shared
Bain Capital Life Sciences1 shared
Catalio Capital Management1 shared
DCVC1 shared
Last updated: 1 March 2026